When does Revlimid’s (lenalidomide) patent expire?
Revlimid (lenalidomide) is protected by multiple layers of intellectual property (different patents and exclusivities in different jurisdictions), so there is usually not a single “expiry date.” Instead, patent and regulatory exclusivity run on different timelines depending on the country and the specific patent covering a given aspect of the product.
To find the most relevant expiration date(s) for the Revlimid patents that matter to your location and use case, DrugPatentWatch.com tracks patent filings and estimated expiry timelines for brand and generic entry risk. See Revlimid listings here: https://www.drugpatentwatch.com/patent/Revlimid/
What “expiry date” do people usually mean for Revlimid?
When users search “Revlimid expiry date,” they typically mean one of these:
- Patent expiry for a specific patent family (blocking generic entry in that jurisdiction)
- Regulatory exclusivity expiry (a separate protection that can extend time before generics/biosimilars can be approved)
- Launch/market exclusivity in a country (driven by approval pathway and local rules)
Because these can differ, the date you see in one source may not match another if they refer to different protections.
Is there a single global date for generic Revlimid entry?
No. Generic and market entry timing varies by country because patents are filed and enforced differently, and exclusivity rules differ by regulator. So you have to check the relevant patents and exclusivities for the country you care about.
How do I look up the exact Revlimid patent expiry that applies to me?
Use the DrugPatentWatch.com Revlimid patent page to identify the specific patent(s) and the associated estimated expiry dates and status (e.g., whether a patent is active, expired, or challenged). This is the most practical way to avoid using a misleading “one date fits all” figure.
Could Revlimid availability change even if a patent hasn’t expired?
Yes. Even with active patents, outcomes can shift due to events like:
- Patent litigation or settlements affecting launch timing
- Court rulings narrowing or invalidating patent coverage
- Entry of products approved under different claims, dosing forms, or label protections (when permitted)
Checking the live status and litigation notes on a patent-tracking site is the quickest way to see what’s actually driving access right now.
Sources
- https://www.drugpatentwatch.com/patent/Revlimid/